Natixis Asset Management increased its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,790 shares of the medical research company’s stock after buying an additional 76 shares during the period. Natixis Asset Management’s holdings in Amgen were worth $801,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the company. Renaissance Investment Group acquired a new stake in Amgen during the fourth quarter worth $242,000. Curbstone Financial Management acquired a new stake in Amgen during the fourth quarter worth $440,000. EisnerAmper Wealth Management increased its stake in Amgen by 9.2% in the fourth quarter. EisnerAmper Wealth Management now owns 3,174 shares of the medical research company’s stock worth $515,000 after buying an additional 267 shares in the last quarter. Gerstein Fisher increased its stake in Amgen by 1.0% in the third quarter. Gerstein Fisher now owns 9,359 shares of the medical research company’s stock worth $1,294,000 after buying an additional 97 shares in the last quarter. Finally, West Oak Capital increased its stake in Amgen by 7.8% in the fourth quarter. West Oak Capital now owns 10,127 shares of the medical research company’s stock worth $1,643,916 after buying an additional 735 shares in the last quarter.

Amgen, Inc. (NASDAQ:AMGN) traded up 2.16% during midday trading on Friday, reaching $156.08. 4,577,287 shares of the company traded hands. The stock has a market capitalization of $117.74 billion and a P/E ratio of 18.63. The firm has a 50-day moving average of $157.50 and a 200-day moving average of $157.02. Amgen, Inc. has a 1-year low of $130.09 and a 1-year high of $181.81.

Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 28th. The medical research company reported $2.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.34. The company earned $5.72 billion during the quarter, compared to analysts’ expectations of $5.32 billion. During the same quarter last year, the firm earned $2.30 EPS. Amgen’s revenue for the quarter was up 13.8% on a year-over-year basis. On average, analysts predict that Amgen, Inc. will post $10.08 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 8th. Shareholders of record on Tuesday, February 16th will be paid a $1.00 dividend. This is a boost from Amgen’s previous quarterly dividend of $0.47. The ex-dividend date of this dividend is Thursday, February 11th. This represents a $4.00 annualized dividend and a yield of 2.56%.

A number of equities analysts recently issued reports on the stock. Credit Suisse assumed coverage on shares of Amgen in a research note on Tuesday, January 19th. They issued an “outperform” rating and a $205.00 price target on the stock. Vetr cut shares of Amgen from a “strong-buy” rating to a “buy” rating and set a $166.85 price target on the stock. in a research note on Monday, October 19th. Jefferies Group reiterated a “buy” rating on shares of Amgen in a research note on Saturday, January 9th. Wells Fargo assumed coverage on shares of Amgen in a research note on Friday, December 4th. They issued a “market perform” rating on the stock. Finally, Piper Jaffray reiterated an “overweight” rating and issued a $200.00 price target on shares of Amgen in a research note on Monday, October 12th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $184.88.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.

12 Month Chart for NASDAQ:AMGN

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.